BlueLys

November 14th - Pre-Market Report on the Following Picks: (PINK:TAGG), (OTC:CBIS), (OTC:AMBS), (PINK:PMEA)

 

New York, NY -- (ReleaseWire) -- 11/14/2012 --TagLikeMe Corp. (PINK:TAGG) announced that its unique new count increased 1800 percent in the month of October. The stock reacted positively to the news. It traded in the range of $0.05 and $0.08 during its latest trading session. The stock had opened at $0.06 and closed at $0.07, up 25 percent from its previous close of $0.06.

TagLikeMe stock shows neutral trend and has its first support level at $0.06 while it faces the resistance at $0.10. The company is engaged in software industry and offers cloud based apps and software.

Get the latest news and reports on TAGG here: PINK:TAGG), Trend Analysis Report" rel="nofollow" href="http://www.wallstreetreport.net/market-scan/?symbol=TAGG">TagLikeMe (PINK:TAGG), Trend Analysis Report

Cannabis Science Inc. (OTC:CBIS) reported the appointment of Chad S. Johnson to its Board of Directors. Mr. Johnson will also serve as General Counsel for the company. Cannabis Science stock reacted positively to the news and it closed its latest trading session at $0.07, up 12.06 percent from its previous close of $0.06. The stock opened the session at $0.06 and touched its highest price point at $0.08.

Cannabis Science stock is currently going through bullish phase and the stock may touch $0.08 in the coming sessions. The company is a development stage concern and develops phytocannabinoid based pharma products.

Find out if the momentum could continue for CBIS here: Cannabis Science (OTC:CBIS), Trend Analysis Report

Amarantus BioSciences Inc. (OTC:AMBS) stock shows bullish trend on its MACD chart. However, in its latest trading session, the stock closed its latest trading session at $0.06, down 15.90 percent from its previous close of $0.07. In the coming sessions, the stock may touch $0.05 level. Upon breaching this level, its next support level would be at $0.04.

Amarantus BioSciences is a biotechnology company and provides treatments for various ailments such as traumatic brain injury and Parkinsons disease. The company also reported about the appointment of Dr. Robert J. Zimmerman as its product development advisor.

Find out if a bounce back is imminent for AMBS here: Amarantus Biosciences Inc. (OTC:AMBS), Trend Analysis Report

P. M. & E Inc. (PINK:PMEA) traded in the range of $0.18 and $0.46 during its latest trading session. The stock had opened at $0.42 and closed at $0.24, down 27.27 percent from its previous close of $0.33. P. M. & E stock shows neutral trend on its MACD chart and has its first support level at $0.05 while it faces the resistance at $0.25.

If the stock breaches $0.25, it may go as high as $0.29. P. M. & E Inc. stock traded in the range of $0.05 and $0.46 in its past 52 weeks. P. M. & E carries out its business through its wholly owned subsidiary SUNCETIX Inc.

Find out more about PMEA by reading the full trend analysis report here: P. M. & E Inc. (PINK:PMEA), Trend Analysis Report

About WallStreetReport.net
WallStreetReport.net issues momentum alerts on stocks that can provide gains to day traders. WallStreetReport.net provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more. WallStreetReport.net monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals WallStreetReport.net is often in the know of several large investor awareness campaigns being deployed.

Timing is everything when trading Penny Stocks. Gain an Edge by joining the WallStreetReport.net newsletter and receiving alerts from a Pro-Active team of researchers. Wall Street Report believes traders should have a chance at successfully trading Penny Stocks and invites traders and investors you to be part of the Free VIP membership.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.WallStreetReport.net

Disclosure: WallStreetReport.net is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetreport.Net website, for complete risks and disclosures.

Contact Info:

Alexander K. Neumann
WALL STREET REPORT
info@WallStreetReport.net
347-905-5009